BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 748
- Registration Number
- NCT01335399
- Locations
- 🇮🇱
Local Institution - 4959, Kfar Saba, Israel
🇷🇴Local Institution - 5352, Bucuresti, Romania
🇵🇱Local Institution - 5254, Gdansk, Poland
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
- Conditions
- HIV, Combination Therapy
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 132
- Registration Number
- NCT01332227
- Locations
- 🇺🇸
Health For Life Clinic Pllc, Little Rock, Arkansas, United States
🇺🇸Eisenhower Medical Center, Palm Springs, California, United States
🇺🇸Consultive Medicine, Daytona Beach, Florida, United States
Diabetic Peripheral Neuropathic Pain (DPNP)
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 178
- Registration Number
- NCT01314222
- Locations
- 🇺🇸
Comprehensive Clinical Development, Inc., St Petersburg, Florida, United States
🇫🇷Local Institution, Nice Cedex 1, France
🇺🇸Office Of Richard S. Cherlin, Md, Los Gatos, California, United States
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
- Conditions
- Hepatitis C
- Interventions
- Biological: Pegylated Interferon Lambda (pegIFNλ)Drug: BMS-790052 (NS5A Inhibitor)Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a)Drug: Ribavirin (RBV)Drug: BMS-650032 (NS3 Protease Inhibitor)Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)Drug: Placebo for Ribavirin (RBV)
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 165
- Registration Number
- NCT01309932
- Locations
- 🇺🇸
Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸Desert Medical Group Inc., Palm Springs, California, United States
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
- Conditions
- Depression
- Interventions
- Drug: Placebo matching with DuloxetineDrug: DuloxetineDrug: Placebo matching with BMS-820836Drug: BMS-820836
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 889
- Registration Number
- NCT01309945
- Locations
- 🇺🇸
Univ Of Penn, Philadelphia, Pennsylvania, United States
🇺🇸Psychiatric Consultants, Pc, Franklin, Tennessee, United States
🇺🇸Pacific Clinical Research Medical Group, Upland, California, United States
Crossover Post-herpetic Neuralgia (PHN)
- Conditions
- Post-Herpetic Neuralgia (PHN)
- Interventions
- Drug: BMS-954561Drug: Placebo
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT01305538
- Locations
- 🇺🇸
Radiant Research, Inc., Akron, Ohio, United States
🇺🇸Medex Healthcare Research, Inc, St. Louis, Missouri, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: PlaceboDrug: Anti-IP-10 Antibody
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 305
- Registration Number
- NCT01294410
- Locations
- 🇺🇸
Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr, Chevy Chase, Maryland, United States
🇺🇸Shafran Gasteroenterology Center, Winter Park, Florida, United States
🇺🇸Minnesota Gastroenterology, Pa, Plymouth, Minnesota, United States
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
- Conditions
- Cancer
- Interventions
- Drug: BMS-906024
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 94
- Registration Number
- NCT01292655
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇨🇦Local Institution, Toronto, Ontario, Canada
Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: PlaceboDrug: BMS-820132
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT01290575
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
🇺🇸Osborne Research Center, Little Rock, Arkansas, United States
🇺🇸Mra Clinical Research, Miami, Florida, United States
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
- Conditions
- Lung Cancer - Non Small Cell Squamous
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1289
- Registration Number
- NCT01285609
- Locations
- 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States
🇺🇸Durham Va Medical Center (111g), Durham, North Carolina, United States